The best Rayyan alternatives in 2026 are Research Gold's screening tool (published accuracy benchmark, self-serve AI screening from $12 per month, PRISMA diagram included on the free tier), Covidence (Cochrane's standard platform, $339 per year as of mid 2026), EPPI-Reviewer (free for UK institutions), ASReview (free and open source), DistillerSR (enterprise), and Abstrackr (free, screening only). Researchers most often switch because Rayyan's flagship ResearchPilot AI is restricted to institutional plans, the free tier lacks a PRISMA flow diagram and automatic duplicate resolution, billing requires at least a quarterly commitment, and no accuracy numbers are published for any of its AI features. This guide compares all six alternatives on pricing, free tier contents, and AI access, then breaks down Rayyan's own pricing so you can decide whether switching is worth it at all.
Rayyan earned its enormous user base honestly: the free tier, the mobile app, and the widely cited Ouzzani et al. 2016 paper made it the default systematic review screening tool for a generation of graduate students. The reasons people leave are just as specific, and all of them come from Rayyan's own pages.
The advertised AI is not the AI you can buy. Rayyan's Advanced plan card promises that you can "accelerate screening with AI agents," yet Rayyan's own help center states that ResearchPilot, the suite containing the AI Reviewer and automatic extraction, is available exclusively on institutional plans. Those plans are custom quoted with a 5-license minimum. An individual researcher cannot purchase Rayyan's flagship AI screening at any price without a sales call, and the contradiction between the plan card and the help center makes it hard to know what a subscription actually includes.
The free tier withholds the two outputs beginners need most. The free plan includes neither the PRISMA flow diagram nor automatic duplicate resolution. You can detect duplicates, but resolving them in bulk requires a paid plan, and your journal-required flow diagram has to be built elsewhere. The much-praised mobile app allows only 100 screening decisions in total on the free tier, and you can invite just 2 free reviewers.
There is no monthly billing. As of mid 2026 the cheapest paid entry is $8.33 per month billed quarterly, roughly $25 up front, and the annual option requires a full year. Researchers who need a paid feature for a single screening month cannot buy one.
No published accuracy evidence. Rayyan claims its duplicate detection was "ranked #1 for accuracy and sensitivity in independent study," but the study is never cited or linked, and no recall, precision, or work-saved numbers are published for the relevance classifier or any ResearchPilot feature. For a methods section that has to defend screening accuracy, that is a real gap.
None of this makes Rayyan a bad tool. It means specific researchers, especially individuals who want verifiable AI-assisted screening and free PRISMA output, are better served elsewhere.
The screening tool with a published accuracy benchmark addresses the exact gaps that push people away from Rayyan. Its AI screening kept 99.1 percent of relevant records (229 of 231) across five published benchmark datasets, its relevance ranking achieved a work saved over sampling at 95 percent recall (WSS@95) of 69 to 93 percent across those datasets, and its deduplication caught 97.4 percent of duplicates with zero wrong merges. The dataset is named, so the numbers are checkable, which no other tool on this list offers for criteria-based AI screening.
Pricing: The free tier covers 3 projects of up to 5,000 records each and, unlike Rayyan's free plan, includes the PRISMA 2020 flow diagram and deduplication. Pro costs $12 per month or $99 per year with unlimited projects and self-serve AI screening; no sales call, no license minimum, no quarterly lock-in.
Strengths: Published, reproducible accuracy numbers. AI screening an individual can actually buy. 7 free database connectors (PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, ClinicalTrials.gov) plus citation chasing, so searching and screening happen in one place, where Rayyan is import-only. Cohen's kappa computed in-app, automated retraction checks, GRADE support on institutional plans, a methods-section generator, and a local-first browser mode that keeps data on your machine.
Weaknesses: No native mobile app (the web interface is responsive), and the platform is younger than Rayyan, so it appears in fewer published methods sections.
Best for: Individual researchers and small teams who want measurable AI screening accuracy and free PRISMA output without an institutional contract.
2. Covidence
Covidence is the platform Cochrane adopted as its standard review production tool in 2015, and it covers the full workflow from screening through data extraction and export to RevMan. Structure and pedigree are its strengths: dual-reviewer screening with conflict resolution, PICOS-framed criteria, an auto-updating PRISMA diagram, and guided extraction templates.
Pricing (as of mid 2026): $339 USD per year for a single review, $907 per year for up to three reviews, both valid 12 months, with unlimited collaborators. The free trial caps at 500 records, there is no monthly option, and their pricing FAQ states there is no student discount.
Strengths: The most mature end-to-end workflow, Cochrane integration, unlimited collaborators on every paid plan.
Weaknesses: You pay per review, per year. On AI, Covidence publicly explained that it declined to release its own LLM screening model after beta recall fell to 66 percent on some reviews, so it offers no criteria-based AI screening at all. See the full list of Covidence alternatives for a deeper breakdown of its pricing and workflow.
Best for: Funded teams and Cochrane authors whose institutions already hold a license.
3. EPPI-Reviewer
EPPI-Reviewer, from University College London's EPPI Centre, is the veteran of the group with two decades of use in health, education, and policy reviews. It is free for UK higher education institutions through JISC licensing, with international subscriptions starting around $500 per year.
Strengths: Full workflow coverage including built-in meta-analysis, real text mining and machine learning prioritization, and unusually strong support for qualitative and mixed-methods synthesis.
Weaknesses: A dated interface and a steep learning curve, particularly for the text mining features.
Best for: UK-based researchers (where it costs nothing) and mixed-methods teams.
4. ASReview
ASReview is an open-source active learning tool from Utrecht University. You screen a few records, the model reorders the rest by predicted relevance, and you keep screening from the top. Published validation studies show it can surface 95 percent of relevant records after screening only 10 to 30 percent of a library.
Strengths: Completely free with no usage limits, transparent open-source models, a simulation mode for benchmarking, and local execution that keeps sensitive data on your machine.
Weaknesses: Screening only. There is no deduplication workflow, no PRISMA diagram, no extraction, and no real collaboration layer, and local installation assumes some technical comfort.
Best for: Solo researchers with very large record sets who are happy to assemble the rest of the pipeline from other tools, for example pairing it with a free reference deduplication utility before import and a free PRISMA 2020 diagram builder after screening.
5. DistillerSR
DistillerSR is the enterprise option, used by health technology assessment agencies and pharmaceutical evidence teams. Pricing is custom and typically starts in the thousands of dollars per year.
Strengths: Continuous AI reprioritization during screening, deeply customizable extraction forms with conditional logic, audit trails built for regulatory submissions, and multi-review program management.
Weaknesses: Cost and complexity. For a single dissertation review it is the wrong size, and like Rayyan's institutional tier, you cannot simply sign up and start.
Best for: Organizations that produce systematic reviews as a core business function.
6. Abstrackr
Abstrackr is a free, web-based screening tool from Brown University's evidence synthesis group. It offers straightforward title and abstract screening with machine-learning relevance predictions and simple collaboration.
Strengths: Free with no record caps, and the prediction model genuinely reduces screening burden on large libraries.
Weaknesses: Development activity is minimal, the interface is bare, and there is no deduplication, PRISMA output, extraction, or mobile support. It is a screening utility, not a platform.
Best for: Zero-budget screening where nothing beyond include and exclude decisions is required.
Switching tools mid-project is the moment most reviews lose data or an audit trail, and the usual trigger is discovering a paywall halfway through screening, exactly what happens when a free Rayyan project suddenly needs duplicate resolution or a PRISMA diagram. If that is where you are, you can import your existing RIS or CSV export and pick up screening with self-serve AI screening in the same afternoon: the free tier covers 5,000 records per project, and the AI benchmark is published so your methods section can defend the workflow.
For anyone deciding whether to stay, here is Rayyan pricing exactly as displayed, as of mid 2026:
| Plan | Quarterly billing | Annual billing | Notes |
|---|
| Free | $0 | $0 | Free forever; 3 active reviews, 2 free reviewers |
| Essential | $8.33 per month | $4.99 per seat per month | PRISMA diagrams and auto duplicate resolution start here |
| Advanced | $13.33 per month | $8.33 per seat per month | 9 active reviews; advertises AI agents (see below) |
| Business/Academic | Not offered | Custom | 5-license minimum, billed annually; ResearchPilot AI |
| Enterprise | Not offered | Custom | SSO, API access, unlimited reviews |
Three structural points matter more than the numbers. First, individual plans are seat-based: premium features apply to reviews you own, and collaborators need their own paid seat for premium access, while free "Reviewer" roles get basic functions only. Second, the quarterly minimum means the real entry cost is about $25 up front rather than $8.33. Third, the AI you probably came for sits above all the listed prices: ResearchPilot is tied to institutional plans, so the effective price of Rayyan's AI Reviewer is a custom quote for at least 5 licenses.
Yes, genuinely: the free tier exists forever, requires no credit card, and handles 3 active reviews with unlimited records in the web app. For pure two-reviewer title and abstract screening it remains one of the best free options available.
The limits appear at the edges of screening. The free plan produces no PRISMA flow diagram, offers duplicate detection without automatic resolution, caps the mobile app at 100 total decisions, includes only 2 free reviewer invitations, and provides standard support only. In practice, most funded reviews hit the PRISMA and deduplication walls at exactly the moment the submission deadline approaches. Budget for either an Essential seat or a free workaround before you start, not after.
The two market leaders split cleanly. Covidence is structured, end-to-end, and Cochrane-endorsed, but costs $339 per year for one review as of mid 2026 and ships no criteria-based AI screening at all. Rayyan is cheaper, mobile-first, and multi-project on the free tier, but gates its serious AI behind institutional licensing and publishes no accuracy evidence. Choose Covidence for funded, Cochrane-style intervention reviews with institutional access; choose Rayyan for free multi-project screening with a mobile app. If the deciding factor is AI screening you can buy and verify as an individual, neither wins. Our dedicated Covidence head-to-head walks through the feature-by-feature detail, and the wider systematic review software roundup places both against every other major platform.
Migration is lower-risk than it feels, because Rayyan keeps your data exportable even after you cancel a paid plan (you revert to free-tier limits rather than losing access).
- Export everything, not just includes. Download your references with decisions, labels, and exclusion reasons so the audit trail survives the move.
- Reconcile counts before importing. Note the number of records imported, duplicates removed, and records excluded at each stage. These figures feed your PRISMA diagram and must match across tools.
- Re-run deduplication in the new tool. Different matchers catch different duplicates; document any newly found ones as an additional deduplication step in your methods.
- Document the switch. One sentence in the methods section stating which tool handled which phase keeps reviewers satisfied and the workflow reproducible.
- Pilot with 50 to 100 records first. Confirm decisions and reasons import correctly before committing the full library.
Screening automation is evolving quickly across every platform mentioned here; our roundup of AI tools for screening and extraction tracks which capabilities are real, which are institution-gated, and which publish evidence.